Carrier Screening for Cystic Fibrosis: Costs and Clinical Outcomes
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Objectives. To evaluate the costs and clinical effects of 16 alternative strategies for cystic fibrosis (CF) carrier screening in the reproductive setting; and to test the sensitivity of the results to assumptions about cost and detection rate, stakeholder perspective, DNA test specificity, chance of nonpaternity, and couples' reproductive plans. Method. Cost-effectiveness analysis. Results. A sequential screening strategy had the lowest cost per CF birth avoided. In this strategy, the first partner was screened with a standard test that identifies 85% of carriers. The second partner was screened with an expanded test if the first partner's screen was positive. This strategy identified 75% of anticipated CF births at a cost of $367,000 each. This figure does not include the lifetime medical costs of caring for a patient with CF, and it assumes that couples who identify a pregnancy at risk will choose to have prenatal diagnosis and termination of affected pregnancies. The cost per CF birth identified is approximately half this figure when couples plan two children. Conclusions. The cost-effectiveness of CF carrier screening depends greatly on couples' reproductive plans. CF carrier screening is most cost-effective when it is performed sequentially, when the information is used for more than one pregnancy, and when the intention of the couple is to identify and terminate affected pregnancies. These conclusions are important for policy considerations regarding population-based screening for CF, and may also have important implications for screening for less common diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Abstract of the United States: 2007
(2007) · Choice Reviews Online · doi:10.5860/choice.45-1769 · Cited by 2,398
RANDOMISED CONTROLLED TRIAL OF GENETIC AMNIOCENTESIS IN 4606 LOW-RISK WOMEN
Tabor, A., Madsen, M., Obel, E., Philip, J., Bang, J., & Gaard-Pedersen, B. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91218-3 · Cited by 869
Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis
Konstan, M. W., Byard, P. J., Hoppel, C. L., & Davis, P. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503303321303 · Cited by 726
Newhouse, J. P., & Taylor, V. (1969) · Cited by 583
Prenatal Genetic Diagnosis in 3000 Amniocenteses
Golbus, M. S., Loughman, W. D., Epstein, C. J., Halbasch, G., Stephens, J. D., & Hall, B. D. (1979) · New England Journal of Medicine · doi:10.1056/nejm197901253000402 · Cited by 254
Prenatal Genetic Diagnosis in 2,000 Amniocenteses
Cho, J. S., Park, Y. W., Kim, S. K., Kim, I. K., Yang, Y. H., Kwon, H. K., & Lee, Y. H. (1999) · Korean Journal of Obstetrics & Gynecology · Cited by 231
What Do Patients Value?: Willingness to Pay for Ultrasound in Normal Pregnancy
Berwick, D. M., & Weinstein, M. C. (1985) · Medical Care · doi:10.1097/00005650-198507000-00005 · Cited by 178
The Cystic Fibrosis Gene: Medical and Social Implications for Heterozygote Detection
Wilfond, B. S. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440200081027 · Cited by 172
Couple screening for cystic fibrosis
Wald, N. (1991) · The Lancet · doi:10.1016/0140-6736(91)92605-2 · Cited by 147
Couple screening for cystic fibrosis
Wald, N., George, L., Wald, N. J., & MacKenzie, I. Z. (1993) · The Lancet · doi:10.1016/0140-6736(93)92403-g · Cited by 121
Low Fetal Loss Rates After Ultrasound-Proved Viability in Early Pregnancy
Simpson, J. L. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03400180089033 · Cited by 117
Willingness to pay for antenatal carrier screening for cystic fibrosis
Donaldson, C., Shackley, P., Abdalla, M., & Miedzybrodzka, Z. (1995) · Health Economics · doi:10.1002/hec.4730040602 · Cited by 109
Knowing for the Sake of Knowing: The Value of Prognostic Information
Asch, D. A., Patton, J. P., & Hershey, J. C. (1990) · Medical Decision Making · doi:10.1177/0272989x9001000108 · Cited by 101
Self-citationSpontaneous abortion and pregnancy outcome after normal first-trimester ultrasound examination.
Wilson, R. D., Kendrick, V., Wittmann, B. K., et al. (1986) · PubMed · Cited by 100
Employer Costs for Employee Compensation, 1986-99
Herman, A. M., & Abraham, K. G. (2000) · Cited by 93
Spontaneous abortion rate in ultrasonographically viable pregnancies.
We, M., Ds, H., & Newton (1988) · PubMed · Cited by 55
Evers‐Kiebooms, G., Denayer, L., & den Berghe, H. V. (1990) · Clinical Genetics · doi:10.1111/j.1399-0004.1990.tb03504.x · Cited by 54
Cystic Fibrosis and DNA Tests—The Implications of Carrier Screening
Nishimi, R. Y. (1993) · JAMA · doi:10.1001/jama.1993.03500150025007 · Cited by 52
Spence, J. E., Buffone, G. J., Rosenbloom, C. L., Fernbach, S. D., Curry, M. R., Carpenter, R., Ledbetter, D. H., O'Brien, W., & Beaudet, A. (1987) · Human Genetics · doi:10.1007/bf00283042 · Cited by 31
Gene therapy for cystic fibrosis: Will it affect the uptake of prenatal carrier screening?
Mennie, M., Compton, M. E., Liston, W. A., & Brock, D. J. H. (1994) · Prenatal Diagnosis · doi:10.1002/pd.1970141210 · Cited by 6
Research works printed but not linked: 21
- U.S. Congress, Office of Technology Assessment. Cystic Fibrosis and DNA Tests, 1992, Implications of Carrier Screening, OTA-BA-532
- 10.2105/AJPH.86.5.684 · doi:10.2105/ajph.86.5.684
- 10.1097/00005650-199105000-00007 · doi:10.1097/00005650-199105000-00007
- Lieu TA, 1994, Obstet Gynecol, 84, 903
- Beaudet AL, 1992, Am J Hum Genet, 50, 439
- 10.1007/BF00291675 · doi:10.1007/bf00291675
- 10.1093/clinchem/34.5.933 · doi:10.1093/clinchem/34.5.933
- Uhlmann WR., 1992, Persp Genet Counseling, 14, 7
- Bureau of Labor Statistics., 1992, Employer Costs for Employee Compensation
- Pauly MV., 1968, Am Econ Rev, 58, 531
- 10.1016/S0002-9378(12)90875-3 · doi:10.1016/s0002-9378(12)90875-3
- 10.1177/096914139500200107 · doi:10.1177/096914139500200107
- 10.2105/AJPH.81.8.992 · doi:10.2105/ajph.81.8.992
- 10.2105/AJPH.82.5.723 · doi:10.2105/ajph.82.5.723
- 10.1177/0272989X9601600208 · doi:10.1177/0272989x9601600208
- Mulivor RA, 1987, Am J Hum Genet, 40, 131
- Wilson RD, 1986, Obstet Gynecol, 67, 352
- Mackenzie WE, 1988, Obstet Gynecol, 71, 81
- 10.1111/j.1471-0528.1985.tb03049.x · doi:10.1111/j.1471-0528.1985.tb03049.x
- 10.1001/jama.1976.03270140023016 · doi:10.1001/jama.1976.03270140023016
- Crandall BF, 1980, Obstet Gynecol, 56, 625
Cited by
Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A., & Sullivan, S. D. (2015) · Value in Health · doi:10.1016/j.jval.2015.02.001 · Cited by 811
Ramsey, S., Willke, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., Cook, J., Glick, H., Liljas, B., Petitti, D., et al. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.00045.x · Cited by 720
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
The death of cost‐minimization analysis?
Briggs, A. H., & O'Brien, B. J. (2001) · Health Economics · doi:10.1002/hec.584 · Cited by 438
Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis
Ades, A. E., Sculpher, M., Sutton, A., Abrams, K., Cooper, N., Welton, N., & Lu, G. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624010-00001 · Cited by 420
Metadata
- Authors
- Asch, D. A., Hershey, J. C., Dekay, M. L., Pauly, M. V., Patton, J. P., Jedrziewski, M. K., Frei, F., Giardine, R., Kant, J. A., & Mennuti, M. T.
- Venue
- Medical Decision Making
- Publisher
- SAGE Publications
- Published
- 1998-01
- Volume
- 18
- Issue
- 2
- Pages
- 202-212
- ISSN
- 0272-989X (ISSN-L)
- 1552-681X
- OpenAlex
- W2614452305
- Cited by
- 375
- References
- 20
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.